SCHEMBL694983

SCHEMBL694983

COC(=O)c1ccc(OCCOc2c(Cl)cc(C)cc2Cl)cc1

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.67
RAB9A P51151 4/20 0.60
TDP1 Q9NUW8 3/20 0.56
L3MBTL1 Q9Y468 3/20 0.56
LMNA P02545 2/20 0.49
GAA P10253 1/20 0.49
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
NPC1 O15118 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
KDM4E B2RXH2 3/20 0.45
HPGD P15428 2/20 0.45
MAPK1 P28482 1/20 0.45
ALDH1A1 P00352 2/20 0.45
POLB P06746 1/20 0.44
BLM P54132 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL695614 0.91 MAPT (0.55) MAPTRAB9ATDP1L3MBTL1LMNA
SCHEMBL695344 0.86 PKM (0.57) L3MBTL1KDM4EMAPK1ALDH1A1
SCHEMBL8408614 0.85 MAPT (0.60) MAPTRAB9ATDP1L3MBTL1LMNA
SCHEMBL1951546 0.82 MAPT (1.00) MAPTRAB9ATDP1L3MBTL1LMNA
SCHEMBL7602449 0.80 MAPT (0.51) MAPTTDP1L3MBTL1SMN1; SMN2HPGD
SCHEMBL8660004 0.78 MAPT (0.51) MAPTRAB9ATDP1L3MBTL1LMNA
SCHEMBL10289213 0.78 REN (0.50) MAPTTDP1L3MBTL1LMNASMN1; SMN2
SCHEMBL1751411 0.77 MAPT (0.49) MAPTTDP1L3MBTL1KDM4EHPGD
SCHEMBL386165 0.77 MAPT (0.89) MAPTRAB9ATDP1L3MBTL1LMNA
SCHEMBL14274445 0.77 MAPT (0.89) MAPTRAB9ATDP1L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115907-A1 NOVEL COMPOUNDS AS INHIBITORS OF RENIN CADILA HEALTHCARE LIMITED (IN) 2012-05-10 US disclosed
EP-2421828-A2 PIPERIDINE DERIVATIVES AS INHIBITORS OF RENIN Cadila Healthcare Limited (IN) 2012-02-29 EP disclosed
WO-2010122580-A2 NOVEL COMPOUNDS AS INHIBITORS OF RENIN CADILA HEALTHCARE LIMITED (IN) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115907-A1 NOVEL COMPOUNDS AS INHIBITORS OF RENIN REN, ACE, AGTR1 MAPT 202/4885RAB9A 529/4885TDP1 2986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.